@FiercePharma: Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: IOYMI: Napp Pharmaceuticals says it is offering England's NHS Remsima for as much as 60% less than Remicade. Article | Follow @EricPFierce
@CarlyHFierce: GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge. Article | Follow @CarlyHFierce
> Teva ($TEVA) beat profit forecasts and raised its outlook on Thursday, in part thanks to a revenue beat from multiple sclerosis med Copaxone. Report
> Bayer's healthcare unit once again drove the German company's sales, with 19.2% growth in that business, to €5.65 billion, overshadowing currency setbacks in its CropScience unit. Report
> Backers of a referendum targeting a reduction in prescription drug costs in California said Wednesday that they'd rounded up more than enough signatures to place their measure on the November 2016 ballot. Report
Medical Device News
@FierceMedDev: Cleveland Clinic developing catheter for delivery of chemotherapy directly into the brain. FierceDrugDelivery story | Follow @FierceMedDev
@VarunSaxena2: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: Theranos authorized new shares that would value the co. at $10B, 3 days before the WSJ article came out. Story | Follow @EmilyWFierce
> Startup Qvella gets $20M Series A to develop rapid pathogen detection test. Story
> Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. News
Biotech News
@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech
@JohnCFierce: Interesting that most of the $PFE/$AGN discussion is around the mechanics of a deal, rather than a backlash against another megamerger. | Follow @JohnCFierce
> Frazier unveils a $262M pure-play biotech venture fund. Story
> Biotech IPOs are staggering as the bulls begin to fade back. Report
> Ultragenyx launches an RNA collaboration with upstart Arcturus. Article
CRO News
> Icon ekes out another quarter of growth despite currency woes. More
> INC boosts its outlook after another big revenue quarter. Report
> Parexel's profits slide as it slashes costs. Story
> Novartis, Qualcomm back trial startup's $6.5M round. Item
> PRA upgrades its Dutch R&D hub with eyes on bioanalytics. Article
Pharma Manufacturing News
> Pfizer and GSK to work together on continuous manufacturing. Item
> Novartis' Sandoz plants in India cited in warning letter. More
> Saline producers face call for FTC probe into shortage, rising prices. Report
> States want FDA to quit seizing their execution drugs. Story
> Aurobindo moves forward with plans for new U.S. plant. Article
Pharma Asia News
> Novartis to close one Indian manufacturing plant as FDA warning bites. Article
> Lupin hopes for more U.S. approvals as earnings drop 35%. Item
> Health insurance companies still being targeted by Chinese hackers. Story
> Cough syrup abuse gets India's attention. More
> BMS sees sharper hep C competition in Japan in Q3. Report
And Finally... Former Merck & Co. ($MRK) CEO Roy Vagelos has amassed a net worth of $1.3 billion from his service on fast-growing Regeneron's board. Report